Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 2
2009 1
2011 1
2012 1
2014 1
2015 1
2016 3
2017 37
2018 28
2019 32
2020 33
2021 30
2022 49
2023 48
2024 30
2025 52
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Results by year

Filters applied: . Clear all
Page 1
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK. Jaiswal MK. Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12. Med Res Rev. 2019. PMID: 30101496 Review.
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval un …
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amy …
Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Huang SL, Shen YL, Peng WY, Ye K, Zheng H. Huang SL, et al. Acta Neurol Belg. 2024 Jun;124(3):895-904. doi: 10.1007/s13760-024-02476-2. Epub 2024 Feb 12. Acta Neurol Belg. 2024. PMID: 38347315
BACKGROUND AND OBJECTIVE: The effectiveness and long-term efficacy of edaravone, a recommended treatment for amyotrophic lateral sclerosis (ALS), has not been examined in real-world settings. ...Two investigators independently screened the retrieved ar …
BACKGROUND AND OBJECTIVE: The effectiveness and long-term efficacy of edaravone, a recommended treatment for amyotrophic la …
Edaravone for amyotrophic lateral sclerosis.
[No authors listed] [No authors listed] Aust Prescr. 2025 Oct;48(5):182-183. doi: 10.18773/austprescr.2025.041. Aust Prescr. 2025. PMID: 41164103 Free PMC article. Review. No abstract available.
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, Günther R, Wolf J, Hermann A, Prudlo J, Cordts I, Lingor P, Löscher WN, Kohl Z, Hagenacker T, Ruckes C, Koch B, Spittel S, Günther K, Michels S, Dorst J, Meyer T, Ludolph AC; German Motor Neuron Disease Network (MND-NET). Witzel S, et al. JAMA Neurol. 2022 Feb 1;79(2):121-130. doi: 10.1001/jamaneurol.2021.4893. JAMA Neurol. 2022. PMID: 35006266 Free PMC article. Clinical Trial.
IMPORTANCE: Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in …
IMPORTANCE: Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral scle …
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Writing Group, et al. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. Lancet Neurol. 2017. PMID: 28522181 Clinical Trial.
BACKGROUND: In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. ...The least-squares mean d …
BACKGROUND: In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not …
Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H. Yoshino H. Expert Rev Neurother. 2019 Mar;19(3):185-193. doi: 10.1080/14737175.2019.1581610. Epub 2019 Feb 27. Expert Rev Neurother. 2019. PMID: 30810406 Review.
Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all skeletal muscles, leading to death, mostly within 2-4 years from onset. ...Expert commentary: Edaravone is the first drug to show effective inhibition of the motor fun …
Amyotrophic lateral sclerosis (ALS) is a progressive fatal disorder that affects all skeletal muscles, leading to death …
Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2).
Tolochko C, Shiryaeva O, Alekseeva T, Dyachuk V. Tolochko C, et al. Int J Mol Sci. 2025 May 29;26(11):5240. doi: 10.3390/ijms26115240. Int J Mol Sci. 2025. PMID: 40508048 Free PMC article. Review.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with damage to motor neurons and leading to severe muscle weakness and, eventually, death. ...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with damage to motor neurons …
Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.
Izenberg A. Izenberg A. Continuum (Minneap Minn). 2023 Oct 1;29(5):1538-1563. doi: 10.1212/CON.0000000000001345. Continuum (Minneap Minn). 2023. PMID: 37851042 Review.
OBJECTIVE: This article reviews the clinical spectrum of amyotrophic lateral sclerosis (ALS), its variant presentations, and the approach to diagnosis and management. ...A coformulation of sodium phenylbutyrate and tauroursodeoxycholic acid has been shown to …
OBJECTIVE: This article reviews the clinical spectrum of amyotrophic lateral sclerosis (ALS), its variant presentations …
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
Bhandari R, Kuhad A, Kuhad A. Bhandari R, et al. Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189. Drugs Today (Barc). 2018. PMID: 29998226 Review.
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a fatal motor neuron degenerative disorder leading to paralysis and eventual death. ...Edaravone is awaiting approval by the European Medicines Agency (EMA) in Europe. E …
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a fatal motor neuron degenerative disor …
Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review.
Gupta D, Vagha S, Dhingra H, Shirsath H. Gupta D, et al. Cureus. 2023 Nov 12;15(11):e48691. doi: 10.7759/cureus.48691. eCollection 2023 Nov. Cureus. 2023. PMID: 38090405 Free PMC article. Review.
Amyotrophic lateral sclerosis (ALS) is a deadly CNS neurodegenerative disease. The way ALS is now managed, from diagnosis to prognosis, is still not ideal despite many studies. Early diagnosis can help ALS patients live longer since prompt treatment can halt …
Amyotrophic lateral sclerosis (ALS) is a deadly CNS neurodegenerative disease. The way ALS is now managed, from diagnos …
345 results